Cited 53 times in
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박병우 | - |
dc.contributor.author | 정준 | - |
dc.date.accessioned | 2020-04-13T17:03:20Z | - |
dc.date.available | 2020-04-13T17:03:20Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 0732-183X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/175627 | - |
dc.description.abstract | PURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years of TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS) group. DFS was defined from the time of enrollment to the time of the first event. RESULTS: A total of 1,293 patients were randomly assigned, and 1,282 patients were eligible for analysis. The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033). The estimated 5-year overall survival rate was 99.4% in the TAM + OFS group and 97.8% in the TAM-only group (hazard ratio, 0.31; 95% CI, 0.10 to 0.94; P = .029). CONCLUSION: The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | American Society of Clinical Oncology | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Surgery (외과학교실) | - |
dc.contributor.googleauthor | Hyun-Ah Kim | - |
dc.contributor.googleauthor | Jong Won Lee | - |
dc.contributor.googleauthor | Seok Jin Nam | - |
dc.contributor.googleauthor | Byeong-Woo Park | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Eun Sook Lee | - |
dc.contributor.googleauthor | Yong Sik Jung | - |
dc.contributor.googleauthor | Jung Han Yoon | - |
dc.contributor.googleauthor | Sung Soo Kang | - |
dc.contributor.googleauthor | Soo-Jung Lee | - |
dc.contributor.googleauthor | Kyong Hwa Park | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Se-Heon Cho | - |
dc.contributor.googleauthor | Sung Yong Kim | - |
dc.contributor.googleauthor | Lee Su Kim | - |
dc.contributor.googleauthor | Byung-In Moon | - |
dc.contributor.googleauthor | Min Hyuk Lee | - |
dc.contributor.googleauthor | Tae Hyun Kim | - |
dc.contributor.googleauthor | Chanheun Park | - |
dc.contributor.googleauthor | Sung Hoo Jung | - |
dc.contributor.googleauthor | Geumhee Gwak | - |
dc.contributor.googleauthor | Jeryong Kim | - |
dc.contributor.googleauthor | Sun Hee Kang | - |
dc.contributor.googleauthor | Young Woo Jin | - |
dc.contributor.googleauthor | Hee Jeong Kim | - |
dc.contributor.googleauthor | Se-Hwan Han | - |
dc.contributor.googleauthor | Wonshik Han | - |
dc.contributor.googleauthor | Min Hee Hur | - |
dc.contributor.googleauthor | Woo Chul Noh | - |
dc.contributor.googleauthor | Korean Breast Cancer Study Group | - |
dc.identifier.doi | 10.1200/JCO.19.00126 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A03727 | - |
dc.relation.journalcode | J01331 | - |
dc.identifier.eissn | 1527-7755 | - |
dc.identifier.pmid | 31518174 | - |
dc.identifier.url | https://ascopubs.org/doi/full/10.1200/JCO.19.00126 | - |
dc.contributor.alternativeName | Park, Byeong Woo | - |
dc.contributor.affiliatedAuthor | 박병우 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.citation.volume | 38 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 434 | - |
dc.citation.endPage | 443 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL ONCOLOGY, Vol.38(5) : 434-443, 2020 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.